About Us
We’re committed to providing the tools to help you stay at the forefront of industry advancements. Through our series of articles, webinars and other educational resources, you’ll gain invaluable insights to help you maximize lab performance and provide a higher level of care to your patients.
We’re committed to providing the tools to help you stay at the forefront of industry advancements. Through our series of articles, webinars and other educational resources, you’ll gain invaluable insights to help you maximize lab performance and provide a higher level of care to your patients.
QuidelOrtho Corporation announced today that it has been granted a De Novo request from the U.S. Food and Drug Administration (FDA), allowing the company to market its new Sofia® 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19 to be awarded FDA market clearance. The test is intended for prescription use only and can be used in point-of-care settings.
Search topics, categories and more...
Select multiple filters
Content Type
Category
Topic
About Us
